![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
WP Melega, AE Williams, DA Schmitz, EW DiStefano and AK Cho
Department of Molecular and Medical Pharmacology, UCLA School of Medicine, USA.
To establish whether the actions of D-amphetamine (Amp) and D- methamphetamine (MeAmp) on the striatal dopamine system were equipotent, pharmacokinetic profiles of each drug were applied to an analysis of their respective induced dopamine efflux profiles. Amp or MeAmp (1 and 5 mg/kg i.v.) was administered to chloral hydrate- anesthetized rats; plasma and brain kinetics were then assessed from 5 to 60 min. Dose-dependent increases in Amp and MeAmp plasma levels resulted in proportional increases in striatum levels that were equivalent for both drugs; elimination rates also were similar and were characterized by a first-order decay process. After MeAmp administration, low levels of brain MeAmp metabolites were detected throughout the 1-hr time period; relative to MeAmp, Amp and p-hydroxy- MeAmp levels were less than 10 and 1%, respectively. The drug-induced dopamine efflux profiles in the striatum were characterized by microdialysis; Amp and MeAmp (1, 2.5 and 5 mg/kg i.v.) effected equivalent, dose-dependent increases in extracellular dopamine levels. For both drugs at 5- and 10-min postinjection, increases in drug striatum levels preceded increases in dopamine efflux. In contrast, from the time of the peak dopamine responses observed at 10 to 20 min until the end of the study at 90 min, changes in striatal drug levels were correlated with extracellular dopamine levels; this correlation was similar for both drugs. These results indicate that Amp and MeAmp pharmacokinetics and their subsequent dopamine responses in the striatum are equivalent. The pharmacokinetic analysis can be extended to the interpretation of other comparative studies that assess effects of Amp and MeAmp.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  M. Niwa, A. Nitta, H. Mizoguchi, Y. Ito, Y. Noda, T. Nagai, and T. Nabeshima A Novel Molecule "Shati" Is Involved in Methamphetamine-Induced Hyperlocomotion, Sensitization, and Conditioned Place Preference J. Neurosci., July 11, 2007; 27(28): 7604 - 7615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Baumann, M. A. Ayestas, L. G. Sharpe, D. B. Lewis, K. C. Rice, and R. B. Rothman Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1190 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kuczenski and D. S. Segal Locomotor Effects of Acute and Repeated Threshold Doses of Amphetamine and Methylphenidate: Relative Roles of Dopamine and Norepinephrine J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 876 - 883. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. Metzger, H. M. Haughey, D. G. Wilkins, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein Methamphetamine-Induced Rapid Decrease in Dopamine Transporter Function: Role of Dopamine and Hyperthermia J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1077 - 1085. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. F. Bowyer, G. D. Newport, W. Slikker Jr., B. Gough, S. A. Ferguson, and J. Tor-Agbidye An Evaluation of l-Ephedrine Neurotoxicity with Respect to Hyperthermia and Caudate/Putamen Microdialysate Levels of Ephedrine, Dopamine, Serotonin, and Glutamate Toxicol. Sci., May 1, 2000; 55(1): 133 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Rivière, W. B. Gentry, and S. M. Owens Disposition of Methamphetamine and Its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1042 - 1047. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Rivière, K. A. Byrnes, W. B. Gentry, and S. M. Owens Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamphetamine and Its Metabolite Amphetamine in the Rat J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1220 - 1226. [Abstract] [Full Text]
|
|
|
|
|
|
W. P. Melega, A. K. Cho, D. Schmitz, R. Kuczenski, and D. S. Segal l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of In Vivo Deprenyl-Derived l-Methamphetamine J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 752 - 758. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Y. Lin, E. W. Di Stefano, D. A. Schmitz, L. Hsu, S. W. Ellis, M. S. Lennard, G. T. Tucker, and A. K. Cho Oxidation of Methamphetamine and Methylenedioxymethamphetamine by CYP2D6 Drug Metab. Dispos., September 1, 1997; 25(9): 1059 - 1064. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Segal and R. Kuczenski Repeated Binge Exposures to Amphetamine and Methamphetamine: Behavioral and Neurochemical Characterization J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 561 - 573. [Abstract] [Full Text]
|
|
|
|
|
|
R. Kuczenski, W. P. Melega, A. K. Cho, and D. S. Segal Extracellular Dopamine and Amphetamine After Systemic Amphetamine Administration: Comparison to the Behavioral Response J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 591 - 596. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Segal and R. Kuczenski An Escalating Dose "Binge" Model of Amphetamine Psychosis: Behavioral and Neurochemical Characteristics J. Neurosci., April 1, 1997; 17(7): 2551 - 2566. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
